Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 3/20 | 0.47 |
| ▸ | EPRS1 | P07814 | 3/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | RARA | P10276 | 2/20 | 0.37 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | RARG | P13631 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757979 | 0.87 | KMO (0.41) | RXFP1KMOEPRS1SMN1; SMN2 | |
| SCHEMBL3745600 | 0.80 | KMO (0.47) | KMO | |
| SCHEMBL3749594 | 0.79 | KMO (0.44) | KMOSMN1; SMN2 | |
| SCHEMBL3752002 | 0.77 | KMO (0.44) | KMOSMN1; SMN2 | |
| SCHEMBL3758452 | 0.74 | KMO (0.58) | RXFP1KMOEPRS1RARARARB | |
| SCHEMBL3759839 | 0.72 | HPGDS (0.42) | KMO | |
| SCHEMBL3747199 | 0.70 | SMN1; SMN2 (0.42) | RXFP1KMOSMN1; SMN2 | |
| SCHEMBL3747338 | 0.68 | SMN1; SMN2 (0.42) | RXFP1KMOSMN1; SMN2 | |
| SCHEMBL3759878 | 0.68 | ALDH1A1 (0.39) | EPRS1PTGFR | |
| SCHEMBL13054024 | 0.68 | ALDH1A1 (0.43) | KMORARARARBRARGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | RXFP1 2024/4885KMO 533/4885EPRS1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.